Catalog No.:AA009C1L

1421373-65-0 | N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide

Name: Name:N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
Brand: AABLOCKS
SKU: AA009C1L
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

99%

in stock

$6.00 $4.00

- +

5mg

99%

in stock

$8.00 $6.00

- +

10mg

99%

in stock

$11.00 $8.00

- +

250mg

99%

in stock

$15.00 $11.00

- +

99%

in stock

$46.00 $32.00

- +

99%

in stock

$159.00 $111.00

- +

25g

98%

in stock

$610.00 $427.00

- +

100g

98%

in stock

$1,640.00 $1,148.00

- +

Technical Information
Properties
Upstream Synthesis Route
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Upstream Synthesis Route
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA009C1L

Chemical Name:

N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide

CAS Number:

1421373-65-0

Molecular Formula:

C28H33N7O2

Molecular Weight:

499.6073

MDL Number:

MFCD27988062

SMILES:

C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC

Properties

Computed Properties

Complexity:

752

Covalently-Bonded Unit Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

3.7

Upstream Synthesis Route

1421373-36-5

1421373-65-0

[1]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn65;66

[2]Patent:CN106674202,2017,A,.Locationinpatent:Paragraph0072

[3]Patent:CN107043369,2017,A,.Locationinpatent:Paragraph0527;0528;0529;0530;0531;0532

[4]Patent:CN108929311,2018,A,.Locationinpatent:Paragraph0244-0247

[5]Patent:CN108623567,2018,A,.Locationinpatent:Paragraph0068;0069;0070

[6]Patent:CN107522690,2017,A,.Locationinpatent:Paragraph0030;0031;0035;0036;0040;0041;0045;0046

[7]Patent:CN108218839,2018,A,.Locationinpatent:Paragraph0031

1421372-66-8

814-68-6

1421373-65-0

[1]Patent:CN109134435,2019,A,.Locationinpatent:Paragraph0056-0074

[2]Patent:CN106543060,2017,A,.Locationinpatent:Paragraph0053-0055

[3]Patent:CN108129342,2018,A,.Locationinpatent:Paragraph0057;0058;0059

[4]Patent:CN107216313,2017,A,.Locationinpatent:Paragraph0074;0074

[5]JournalofHeterocyclicChemistry,2017,vol.54,#5,p.2898-2901

[6]Patent:CN106366072,2017,A,.Locationinpatent:Paragraph0079;0080;0081;0082;0111-0115

[7]Patent:CN106366022,2017,A,.Locationinpatent:Paragraph0084;0085;0086;0087;0088;0089;0090

[8]Patent:CN107793413,2018,A,.Locationinpatent:Paragraph0191-0194

[9]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23

[10]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn65

[11]JournalofMedicinalChemistry,2014,vol.57,#20,p.8249-8267

1421372-66-8

625-36-5

1421373-65-0

[1]Patent:WO2013/14448,2013,A1,.Locationinpatent:Page/Pagecolumn66

[2]Patent:CN106699736,2017,A,.Locationinpatent:Paragraph0045;0046;0047;0048;0049

[3]Patent:CN107188888,2017,A,.Locationinpatent:Paragraph0073-0075

1032452-86-0

1421373-65-0

[1]Patent:CN104817541,2017,B,.Locationinpatent:Paragraph0047-0048

[2]JournalofChemicalResearch,2015,vol.39,#6,p.318-320

[3]Patent:CN105601620,2016,A,.Locationinpatent:Paragraph0102;0103;0104;0105;0106;0107;0108-0114

954421-16-0

1421373-65-0

[1]Patent:CN104910049,2016,B,.Locationinpatent:Paragraph0049;0050

Downstream Synthesis Route

1075705-01-9

1421373-65-0

[1]Patent:WO2013/14448,2013,A1

[2]Patent:WO2013/14448,2013,A1

[3]Patent:WO2013/14448,2013,A1

[4]JournalofChemicalResearch,2015,vol.39,p.318-320

[5]Patent:CN106366072,2017,A

[6]Patent:CN106366022,2017,A

[7]Patent:CN106543060,2017,A

[8]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23

[9]Patent:CN104817541,2017,B

[10]JournalofHeterocyclicChemistry,2017,vol.54,p.2898-2901

[11]Patent:CN106967050,2017,A

[12]Patent:CN107188888,2017,A

[13]Patent:CN107216313,2017,A

[14]Patent:CN107216313,2017,A

[15]Patent:CN107793413,2018,A

[16]Patent:CN108129342,2018,A

[17]Patent:CN108129342,2018,A

[18]Patent:CN108623567,2018,A

1421372-66-8

1421373-65-0

[1]Patent:WO2013/14448,2013,A1

[2]Patent:CN106674202,2017,A

[3]Patent:CN108623567,2018,A

1421372-66-8

814-68-6

1421373-65-0

[1]Patent:CN109134435,2019,A.Locationinpatent:Paragraph0056-0074

[2]Patent:CN106543060,2017,A.Locationinpatent:Paragraph0053-0055

[3]Patent:CN108129342,2018,A.Locationinpatent:Paragraph0057;0058;0059

[4]Patent:CN107216313,2017,A.Locationinpatent:Paragraph0074;0074

[5]JournalofHeterocyclicChemistry,2017,vol.54,p.2898-2901

[6]Patent:CN106366072,2017,A.Locationinpatent:Paragraph0079;0080;0081;0082;0111-0115

[7]Patent:CN106366022,2017,A.Locationinpatent:Paragraph0084;0085;0086;0087;0088;0089;0090

[8]Patent:CN107793413,2018,A.Locationinpatent:Paragraph0191-0194

[9]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23

[10]Patent:WO2013/14448,2013,A1.Locationinpatent:Page/Pagecolumn65

[11]JournalofMedicinalChemistry,2014,vol.57,p.8249-8267

1421372-66-8

625-36-5

1421373-65-0

[1]Patent:WO2013/14448,2013,A1.Locationinpatent:Page/Pagecolumn66

[2]Patent:CN106699736,2017,A.Locationinpatent:Paragraph0045;0046;0047;0048;0049

[3]Patent:CN110437209,2019,A.Locationinpatent:Paragraph0547-0552

[4]Patent:CN107188888,2017,A.Locationinpatent:Paragraph0073-0075

1421372-67-9

1421373-65-0

[1]Patent:WO2013/14448,2013,A1

[2]Patent:WO2013/14448,2013,A1

[3]Patent:WO2013/14448,2013,A1

[4]JournalofMedicinalChemistry,2014,vol.57,p.8249-8267

[5]EuropeanJournalofMedicinalChemistry,2017,vol.135,p.12-23

[6]Patent:CN107188888,2017,A

[7]Patent:CN107216313,2017,A

[8]Patent:CN107793413,2018,A

[9]Patent:CN108623567,2018,A

[10]Patent:CN109134435,2019,A

Literature

Title: L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20161001

Title: Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

Journal: Journal of medicinal chemistry 20160728

Title: Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Journal: Therapeutic advances in respiratory disease 20160401

Title: Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20160401

Title: Osimertinib: First Global Approval.

Journal: Drugs 20160201

Title: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

Journal: Journal of hematology & oncology 20160101

Title: Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Journal: Journal of structural biology 20151201

Title: Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Journal: JAMA oncology 20151001

Title: Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150901

Title: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

Journal: The Lancet. Oncology 20150901

Title: The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).

Journal: Annals of translational medicine 20150501

Title: Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Journal: Current opinion in oncology 20150301

Title: Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?

Journal: Drug design, development and therapy 20150101

Title: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Journal: Cancer discovery 20140901

Title: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20130201

Title: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Journal: The New England journal of medicine 20040520

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS